A case report of a patient with bulky uterine cervical neoplasm who achieved complete response with “intentional internal high-dose policy” high-dose-rate interstitial brachytherapy

Tairo Kashihara, MD, PhD, Kazuma Kobayashi, MD, Kotaro Iijima, MSc, Naoya Murakami, MD, PhD, Ken Yoshida, MD, PhD, Kae Okuma, MD, PhD, Satoshi Nakamura, PhD, Kana Takahashi, MD, PhD, Koji Inaba, MD, PhD, Hiroshi Igaki, MD, PhD, Yuko Nakayama, MD, PhD, Tomoyasu Kato, MD, PhD, Takashi Uno, MD, PhD, Jun Itami, MD, PhD

Abstract
Rationale Gynecological high-dose-rate (HDR) brachytherapy has progressed for years, but it remains difficult for bulky tumors to be controlled locally. Dose limitations to organs at risk (OARs) are invariably obstacles in increasing the prescription dose. Additionally, it is controversial that the excessive hyperdose sleeve, the volume receiving a dose equal to or greater than twice the reference dose, should be eliminated in gynecological HDR brachytherapy. On the other hand, the technique of simultaneous integrated protection was reported for large hepatocellular carcinoma treatment, and similarly, internal high-dose brachytherapy could be used for treating bulky cervical carcinoma.

Patient Concerns A 54-year-old female had irregular genital bleeding and lost 13 kg in one year.

Diagnosis She was diagnosed with T3bN1M0 cervical cancer in another hospital. The transverse diameter of the primary tumor was 10.5 cm.

Interventions The whole pelvis and para-aortic lymph node were irradiated with a total of 50 Gy in 25 fractions, but the size of the tumor showed only a slight decrease to 8.9 cm. After external beam radiotherapy, first-time high-dose-rate interstitial brachytherapy (HDR-ISBT) was administered without “intentional internal high-dose (IIHD) policy,” the technique of high-dose administration to only the inside of the tumor. Considering the rectum dose limitation, in the additional 2 times of brachytherapy, “IIHD policy” HDR-ISBT was applied. In the second and third HDR-ISBT, the percentage of the volume exposed to 200% of the prescribed dose for high-risk clinical target volume increased by 241% and 204% compared with the first HDR-ISBT, while the doses to OARs were not significantly higher than those of the first-time HDR-ISBT.

Outcomes Complete response was obtained, and no recurrence findings and side effects caused by HDR-ISBT have been detected for 2 years and 9 months.

Lessons To our knowledge, this is the first report of IIHD HDR-ISBT for bulky cervical cancer. This technique can be the solution for treating bulky cervical cancer.

Abbreviations: HDR = high-dose rate, HDR-ISBT = high-dose-rate interstitial brachytherapy, HHD = homogenous dose distribution, HRCTV = high-risk clinical target volume, IGBT = image-guided brachytherapy, IIHD = intentional internal high dose.
OAR = organ at risk, SCC = squamous cell carcinoma, SIB = simultaneous integrated boost, SIP = simultaneous integrated protection.

**Keywords:** ablative radiation therapy, brachytherapy, bulky tumor, gynecological neoplasm, uterine cervical neoplasm

1. Introduction

Gynecological high-dose-rate (HDR) brachytherapy has progressed for years through the introduction of image-guided brachytherapy. Nonetheless, it remains difficult for locally advanced cervical cancer to be controlled locally.\[1\] Though interstitial brachytherapy (ISBT) is known to bring high local dose to or greater than twice the reference dose, should be eliminated in the excessive hyperdose sleeve, the volume receiving a dose equal or not arises. In head and neck brachytherapy, it has been demonstrated that internal high-dose distribution in the tumor is better.

Meanwhile, in recent years, hypofractionated radiotherapy has become a common treatment method, and the question whether internal high-dose distribution in the tumor is better or not arises. In head and neck brachytherapy, it has been demonstrated that the excessive hyperdose sleeve, the volume receiving a dose equal to or greater than twice the reference dose, should be eliminated in HDR brachytherapy.\[9\] On the other hand, the policy of simultaneous integrated boost (SIB) with simultaneous integrated protection (SIP) was reported for large hepatocellular carcinoma.\[10\] This policy means enhancing irradiation dose to the tumor while saving OARs with SIB. However, for gynecological ISBT, no study of internal high-dose distribution has been reported thus far. We assumed that the policy of administering high dose to only the inside of the tumor in saving OARs in HDR-ISBT could be the solution for bulky cervical carcinoma to control the primary tumor safely. We named this technique as “intentional internal high-dose (IHHD) policy” HDR-ISBT in contradistinction to conventional “homogeneous dose distribution (HDD) policy” HDR-ISBT. Herein, we present a case of bulky cervical cancer treated with this “IHHD policy” HDR-ISBT safely and effectively.

2. Case presentation

A 54-year-old female was diagnosed with cervical clear cell carcinoma in another hospital. The tumor-node-metastasis stage according to the UICC 8th edition was clinical T3bN1M0, and bilateral parametrical infiltration was detected. The transverse maximum diameter of the primary tumor was 10.5 cm (volume, 532 cm³). A total of 50 Gy in 25 fractions for the whole pelvis and para-aortic lymph node was irradiated using the 2 opposed-fields technique external beam radiotherapy therapy, but the size of the primary tumor decreased by only 1.6 cm (the tumor volume, 393 cm³). HDR-ISBT was recommended to control the primary tumor, and then, she was referred to our institution. First-time HDR-ISBT was administered without IHHD policy. The procedure of ISBT for patients with cervical cancer has been described by Murakami et al and Kashihara et al.\[11,13\]

The first ISBT was performed with “HDD policy.” The maximum dose to the most exposed 0.1 cc (D0.1 cc) and 2.0 cc (D2.0 cc) for the rectum, sigmoid and bladder (rectum D0.1cc/2.0cc, sigmoid D0.1cc/2.0cc and bladder D0.1cc/2.0cc) and the dose indexes for high-risk clinical target volume (HRCTV) coverage (HRCTV D90/V100) were evaluated in the first ISBT. Dose indexes for high-risk clinical target volume (HRCTV) coverage (HRCTV D90/V100) were evaluated in the first ISBT. Rectum D0.1cc/2.0cc was 572 cGy/491 cGy and HRCTV D90 and V100/200/300/400/500 were 630 cGy and 93.8%/13.8%/4.2%/2.1%/1.2%, respectively. In our institution, the criteria of the rectum D2.0cc < 75 Gy have been adopted as a rectum dose limitation in reference to the prospective multicenter EMBRACE (Image guided intensity modulated external beam radiochemotherapy and MRI based adaptive brachytherapy in locally advanced cervical cancer) study.\[4,5\] Considering this rectum dose limitation, additional 2 times of brachytherapy can be tolerable after the first time HDR-ISBT. On the other hand, the primary tumor would not be controlled with “HDD policy” HDR-ISBT because the tumor diameter was still greater than 6 cm.\[3\] Therefore, “IHHD policy” HDR-ISBT was adopted to control the bulky primary tumor safely.

The needles were kept inserted until the third-time ISBT was finished and fixed with silicon putty for laboratory purposes (Fig. 1). Simulation computed tomography was performed at each ISBT to validate that the needle did not move from the first-time simulation computed tomography. Additionally, magnetic resonance imaging was performed after the first-time ISBT to evaluate the dose to OARs and HRCTV more accurately. In the second and third HDR-ISBT, the IHHD ISBT was performed, and the dose-volume histograms of all the 3 ISBTs are shown in Table 1. The prescribed reference dose per fraction (100% isodose) was 6 Gy in all ISBTs. Doses to the OARs (rectum/sigmoid/bladder, D0.1cc/0.2cc) and HRCTV D90/V100 were not significantly different between the first and the second/third ISBT, but HRCTV V200/300/400/500 were significantly higher in the second and third ISBT than in the first one (Table 1, Fig. 2). No adverse acute events caused by needle insertion and IHHD ISBT were detected. Additionally, complete response (Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.1) was achieved, and no recurrence findings or late adverse events caused by HDR-ISBT have been detected for 2 years and 9 months.

3. Discussion and Conclusions

A 54-year-old female with cervical cancer who received “IHHD policy” HDR-ISBT after EBRT of 50 Gy in 2.5 fractions was reported in this paper. To our knowledge, this is the first report that describes the effectiveness and safety of “IHHD policy” HDR-ISBT. Crane and Koay\[10\] proposed the ablative dose painting SIP irradiation for large liver tumors. This strategy is reasonable for escalating the dose to the tumor, while meeting OAR dose limitations. However, respiratory movement has to be considered...
Table 1

| Parameters | 1st time | 2nd time | 3rd time |
|------------|----------|----------|----------|
| Rectum $D_{2.0cc}$ | 491 cGy | 486 cGy | 510 cGy |
| Rectum $D_{0.1cc}$ | 572 cGy | 560 cGy | 573 cGy |
| Bladder $D_{2.0cc}$ | 440 cGy | 480 cGy | 507 cGy |
| Bladder $D_{0.1cc}$ | 404 cGy | 521 cGy | 561 cGy |
| Sigmoid $D_{2.0cc}$ | 414 cGy | 464 cGy | 472 cGy |
| Sigmoid $D_{0.1cc}$ | 562 cGy | 519 cGy | 640 cGy |
| HR-CTV $D_{90}$ | 630 cGy | 651 cGy | 631 cGy |
| HR-CTV $V_{100}$ | 214 cc (93.8%) | 216 cc (95.6%) | 217 cc (94.4%) |
| HR-CTV $V_{200}$ | 31.5 cc (13.8%) | 75.4 cc (33.3%) | 65.0 cc (28.2%) |
| HR-CTV $V_{300}$ | 9.6 cc (4.2%) | 32.4 cc (14.3%) | 27.0 cc (11.6%) |
| HR-CTV $V_{400}$ | 4.8 cc (2.1%) | 15.5 cc (6.9%) | 12.3 cc (5.4%) |
| HR-CTV $V_{500}$ | 2.7 cc (1.2%) | 8.6 cc (3.8%) | 7.0 cc (3.0%) |

The dose-volume histograms of the 3 ISBTs.

+$D_{0.1cc}$ = maximum dose to the most exposed 0.1 cc of the organ, $D_{2.0cc}$ = maximum dose to the most exposed 2.0 cc of the organ, HR-CTV $D_{X}$ = minimum dose covering X% of the high-risk CTV, HR-CTV $V_{Y}$ = percent of the high-risk CTV receiving Y % of the prescription dose.
in abdominal external beam IHID SIP irradiation, because high-dose irradiation to OARs is a significantly dangerous treatment. On the other hand, though there is a problem of internal organ motion,[13] “IHID policy” HDR-ISBT is a safer approach as far as peripheral dose is maintained around 6 Gy because needles for ISBT are inserted into the tumor.

Kuroda et al[16] reported that 5-year overall survival rate of International Federation of Gynecology and Obstetrics stage IIIB (FIGO) cervical cancer patients treated by definitive radiation therapy was 52.4%. However, in stage IIIA patients, bilateral parametrial infiltration and bulky disease (> 5 cm) had significantly higher recurrence rate.[17] In this case, the transverse maximum diameter of the primary tumor was 10.5 cm with bilateral parametrial infiltration, and in recent study,[18] disease-free survival rate of the patients who have stage IIIA cervical cancer more than 8 cm was 16.7%. Another previous study revealed that hypoxia may contribute to lower local control of bulky tumor. Hockel et al[19] reported that hypoxic cervical cancer led to poorer outcome in RT, and larger-sized tumor was related to hypoxia. In an animal experimental study by Epel et al[20] it was demonstrated that boost irradiation to hypoxic area inside of the tumor significantly enhanced the local control.

“IHID policy” HDR-ISBT is a reasonable policy also in this point, and therefore, it would be a new strategy for bulky tumor. There are 2 limitations in this report. One is that complete response might be obtained with “HDD policy” HDR-ISBT. Nevertheless, after the first-time ISBT, the tumor was still bulky, and the size was more than 8 cm. According to Potter et al,[21] when the HRCTV volume is larger than 30 cm³, HRCTV D90 needs to receive higher than 85 Gy. Nevertheless, EBRT 50 Gy in 25 fractions and 3 times of ISBT (HRCTV D90 of the first-time ISBT was 630 cGy) resulted in approximately 76 Gy, much less than 85 Gy. Therefore, it would be very difficult for the tumor to be controlled with “HDD policy.” To validate the effectiveness of this technique, a larger controlled study would be needed. The other is that the follow-up period is about 3 years, and then recurrence and late side effects can occur after this. Longer follow-up will be needed to conclude that “IHID policy” HDR-ISBT is sufficiently safe.

In summary, this is the first report of “IHID policy” HDR-ISBT for bulky cervical cancer. This policy can be the solution for bulky cervical cancer. Long-term follow-up will be needed to evaluate late side effects.

Acknowledgments

The authors thank Editage (www.editage.jp) for English-language editing.

Author contributions

All authors conceived of the study, and participated in its design and coordination and helped to draft the manuscript. They read and approved the final manuscript.

References

[1] Datta NR, Stutz E, Gomez S, et al. Efficacy and safety evaluation of the various therapeutic options in locally advanced cervix cancer: a systematic review and network meta-analysis of randomized clinical trials. Int J Radiat Oncol Biol Phys 2019;103:411–37.
[2] Demanes DJ, Rodriguez RR, Bendre DD, et al. High dose rate transperineal interstitial brachytherapy for cervical cancer: high pelvic control and low complication rates. Int J Radiat Oncol Biol Phys 1999;45:103–12.
[3] Itami J, Hara R, Kozuka T, et al. Transperineal high-dose-rate interstitial radiation therapy in the management of gynecologic malignancies. Strahlenther Onkol 2003;179:737–41.
[4] Mendez LC, Weiss Y, D’Souza D, et al. Three-dimensional-guided perineal-based interstitial brachytherapy in cervical cancer: a systematic review of technique, local control and toxicities. Radiother Oncol 2017;123:312–8.
[5] Tanderup K, Fokdal LU, Sturdza A, et al. Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. Radiother Oncol 2016;120:441–6.
[6] Isohashi F, Mabuchi S, Akino Y, et al. Dose-volume analysis of predictors for chronic gastrointestinal complications in patients with cervical cancer treated with postoperative concurrent chemoradiotherapy and whole-pelvic radiation therapy. J Radiat Res 2016;57:668–76.
[7] Kato S, Tran DN, Ohno T, et al. CT-based 3D dose-volume parameter of the rectum and late rectal complication in patients with cervical cancer treated with high-dose-rate intracavitary brachytherapy. J Radiat Res 2010;51:215–21.
[8] Zakariaire R, Hamarneh G, Brown CJ, et al. Association of bladder dose with late urinary side effects in cervical cancer high-dose-rate brachytherapy. Brachytherapy 2017;16:1175–83.
[9] Dutreix A, Marmello G, Wambersie A, Dutreix A, Marinello G, Wambersie A. Dosimétrie du système de Paris. Dosimétrie en Curiethérapie. 1st ed.Paris: Masson; 1982;109–38.
[10] Crane CH, Koay EJ. Solutions that enable ablative radiotherapy for large liver tumors: fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance. Cancer 2016;122:1974–86.
[11] Murakami N, Kasamatsu T, Sumi M, et al. Vaginal tolerance of CT based image-guided high-dose rate interstitial brachytherapy for gynecological malignancies. Radiother Oncol 2014;115:31–9.
[12] Kashiwara T, Murakami N, Tsels N, et al. Hyaluronate gel injection for rectum dose reduction in gynecologic high-dose-rate brachytherapy: initial Japanese experience. J Radiat Res 2019;60:501–8.
[13] Murakami N, Kobayashi K, Kato T, et al. The role of interstitial brachytherapy in the management of primary radiation therapy for uterine cervical cancer. J Contemp Brachytherapy 2016;5:391–8.
[14] Mazeron R, Fokdal MU, Kirshheimer K, et al. Dose–volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study. Radiother Oncol 2016;120:412–9.
[15] Magne N, Chargari C, SanFilippo N, et al. Technical aspects and perspectives of the vaginal mold applicator for brachytherapy of gynecologic malignancies. Radiother Oncol 2010;97:74–7.
[16] Kuroda Y, Murakami N, Morota M, et al. Impact of concurrent chemotherapy on definitive radiotherapy for women with FIGO IIIb cervical cancer. J Radiat Res 2012;53:588–93.
[17] Perez CA, Grigsby PW, Nene SM, et al. Effect of tumor size on the prognosis of carcinoma of the uterine cervix treated with irradiation alone. Cancer 1992;69:2796–806.
[18] Soderini A, Aragona A, Moschen H, et al. 208 Prognostic significance of the central tumor size (CTS) in stages IIb and IIib bulky cervical cancer (CC): proposing a new FIGO staging system. Int J Gynecol Cancer 2019;29:A91.
[19] Hockel M, Schlegner K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509–13.
[20] Epel B, Maggio MG, Barath ED, et al. Oxygen-guided radiation therapy. Int J Radiat Oncol Biol Phys 2018;103:977–84.
[21] Potter R, Tanderup K, Kirisits C, et al. The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol 2018;9:48–60.